BridgeBio Pharma, Inc. (BBIO): what the price requires

At today's price, BridgeBio Pharma, Inc. (BBIO) is priced for today's economics sustained for ~20.9 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/BBIO

Headline

FieldValue
TickerBBIO
CompanyBridgeBio Pharma, Inc.
Current price$82.70/sh
CompositionNet product revenue 72% / License and services revenue 26% / Royalty revenue 2%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisrevenue-multiple
EV / sales paid33.0x
Steady-state operating margin assumed29.5%
Must persist for20.9y

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 11.2% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.8 years.

Reconcile: at the x-ray's 9.3% required return this reads ~15.8 years; the models below use their own rates.

How unusual the bet is: elevated

ReferenceValue
vs own history-0.59σ
sustained it ~10 years at this level14%
implied end-window share0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset—0—
Earnings—0—
Relative6.94x2expensive
Growth5.92x2expensive

Families that call it expensive: Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.0%); the inversion above states its own rate.

Per-Model Detail (n=4)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$0.00—noNegative/zero FCF — equity value floored at $0
DCF Exit MultipleGrowth$0.00—noNegative/zero FCF or EBITDA — equity value floored at $0
Relative ValuationRelative$11.916.94xyesP/S fallback (negative EPS): Sector P/S 4.0x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset——no—
Two-Stage Excess ReturnAsset——no—
Discounted Future Market CapGrowth$51.841.60xyesRev $0.6B, growth 30% (input: historical growth; tapered), Terminal P/S: 9.6x / 12.0x / 14.4x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth$8.0710.25xyesMargin ramp: -50% → 12% over 7yr, rev growth 30% (input: historical growth; tapered)
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative$11.916.94xyesRevenue $0.58B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$1.7b
Interest coverage-9.0x
Share count CAGR (dilution)7.5%
Burning cashyes

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Bullet Takeaways

Bull Case

The gap between what the standard valuation methods show and what the business is doing is the heart of the bull case, and it is wide. Cash-flow and earnings methods systematically undervalue a biotech in the first innings of a drug launch, because they look backward at losses while the value is entirely in the forward ramp. BridgeBio is the clean example: the company still posts large operating losses, so the static methods land far below the price, but those losses are the cost of launching a drug that is selling fast. Attruby (acoramidis) generated $362.4 million in revenue in its first full year, and U.S. net product revenue reached $180.6 million in the first quarter of 2026 alone. A drug nearly matching half its prior full year in a single quarter is not a business in decline; it is a launch curve bending upward.

The adoption data is what makes the ramp credible. As of the end of 2025, Attruby had been prescribed to 6,629 unique patients by 1,632 prescribers, and the company describes it becoming the first-choice therapy for newly diagnosed patients. The clinical case behind that adoption is concrete: real-world evidence shows Attruby reduced diuretic intensification by 43% compared to the incumbent tafamidis, a meaningful outcome difference in a disease where keeping patients out of the hospital is the goal. The filing frames the opportunity around "the size and growth potential of the commercial markets for Attruby," and the global runway is opening: the drug is approved in the U.S., the EU (as Beyonttra), and now Brazil.

The market itself is large and growing. ATTR-CM was long underdiagnosed, and as awareness and screening improve, the patient pool expands, which is why the incumbent's sales have grown rapidly even as new entrants arrive. BridgeBio holds roughly $940 million of liquid assets to fund the launch, and management's authorization of a $500 million buyback signals confidence that the revenue ramp will carry the company to profitability rather than requiring more dilution. The bull case is that a differentiated drug taking first-choice share in a large, expanding market is worth far more than the loss-making income statement suggests, and the methods that anchor on trailing losses are exactly the ones that miss it.

Bear Case

The competitive threat is the bear's strongest ground, because Attruby did not invent the ATTR-CM market; it walked into one already owned by a giant. Pfizer's tafamidis (sold as Vyndaqel and Vyndamax) is the entrenched standard of care, generating $3.9 billion in just the first nine months of 2024, with deep relationships across the cardiologists who treat this disease. Displacing an established drug in a chronic disease is slow and expensive: physicians are cautious about switching stable patients, and the incumbent has years of real-world data and a sales force already in every clinic. BridgeBio is the challenger, and challengers in pharma usually win share at the margin among new patients, not by converting the installed base.

The competition is also getting more crowded, not less. Alnylam's vutrisiran (Amvuttra), a subcutaneous injection given every three months, has entered the ATTR-CM market with analysts projecting peak sales in the billions. A three-way race between an oral incumbent, BridgeBio's oral challenger, and an injectable with a convenience angle means pricing pressure and a fight for every new diagnosis. The filing acknowledges the breadth of the threat, noting competitors include large pharmaceutical "companies worldwide" as well as academic and research organizations, and that these rivals compete not just for patients but for "qualified scientific and management personnel" and trial sites. A single-product company facing two well-funded competitors has concentrated risk: one drug, one disease, two formidable rivals.

The valuation leaves no room for the competition to bite. At roughly 27 times revenue, the price embeds an assumption that BridgeBio eventually earns a near-30% operating margin and grows revenue at its self-funding ceiling for close to two decades. Of comparable fast-growers, only about 14% sustained that pace for even ten years, and BridgeBio is doing it while still deeply unprofitable, with net debt of roughly $1.7 billion and an ongoing cash burn. If Attruby's share gains plateau as Alnylam's injectable takes the convenience-seeking segment and Pfizer defends its base, the revenue ramp the price requires slows, and a 27-times-revenue multiple on a single-drug biotech compresses hard. The bear case is not that Attruby fails; it is selling well. It is that the price assumes near-monopoly economics in a market that is becoming a three-way fight, and the value methods offer no floor if the share war turns out to be the expensive, drawn-out kind.

Valuation

BridgeBio is not yet earning a normal operating profit, so the price is read against its sales rather than its earnings. At about 27 times revenue, the price implies the business eventually earns an operating margin near 30% and grows revenue at its self-funding ceiling for roughly 18 years. That is the bet: a drug launch that not only ramps fast but sustains both rapid growth and rich pharma margins for the better part of two decades.

The method picture is the one that recurs in early-launch biotech, and it should be read with the sector's quirk in mind. The static, backward-looking lenses cannot frame this company: the relative peer-multiple and revenue-multiple methods land far below the price because they apply a normal multiple to current sales, and BridgeBio still loses money, so the earnings methods do not apply. Only the forward-looking methods reach toward the price: the discounted-future-market-cap method, which credits the revenue trajectory, lands within reach, while the margin-trajectory method, which has to assume the operating margin climbs from deeply negative to positive, sits below it. The honest read is that the price is supported only by the forward growth of Attruby; no method anchored on today's loss-making reality comes close. This is normal for a biotech whose value lives in a launching drug, but a buyer should know the price has no support from current fundamentals.

Solvency is the binding constraint on a cash-burning launch. BridgeBio carries net debt of roughly $1.7 billion against about $940 million of liquid assets, and it is still consuming cash as it funds the commercial buildout. The Attruby revenue ramp is what closes that gap, and the company's $500 million buyback authorization signals management believes the cash flow inflection is near enough to return capital rather than hoard it. The most decisive point for the valuation is the single-product concentration: at 27 times revenue the entire price rests on Attruby sustaining a steep ramp and rich margins against two well-funded competitors, so the bet is less about whether the drug works, which it does, and more about how much of a contested market one challenger can durably own.

Catalysts

BridgeBio's catalysts all run through the Attruby launch curve. The drug, approved by the FDA in November 2024, generated $362.4 million in full-year 2025 revenue, including $146.0 million in the fourth quarter, and then $180.6 million of U.S. net product revenue in the first quarter of 2026 within total quarterly revenue of $194.5 million. The adoption metrics underpin the ramp: 6,629 unique patients and 1,632 prescribers as of the end of 2025, with the company positioning Attruby as the first-choice therapy for newly diagnosed ATTR-CM patients.

The forward catalysts are geographic expansion and the path to profitability. Acoramidis is now approved in the U.S., the EU (as Beyonttra), and Brazil, with additional regulatory filings underway, each new market a step-up in the addressable revenue. The company authorized a $500 million share buyback, an unusual move for a company still burning cash and a signal that management expects the revenue ramp to turn cash flow positive.

The competitive milestones are the variable to watch most closely. The ATTR-CM market is now a three-way contest among Pfizer's tafamidis, BridgeBio's Attruby, and Alnylam's injectable Amvuttra, so the quarterly share data, not just BridgeBio's absolute revenue, is what tells investors whether Attruby is holding its first-choice position. The next earnings reports, with the Attruby revenue trajectory, the new-prescriber additions, and any read on competitive share, are the cleanest test of whether the launch sustains the pace the price already assumes.

Peer Cohorts (Per Segment, With Filing Citations)

BridgeBio Pharma (consolidated) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

BridgeBio FY2025 and Q1 2026 results · BridgeBio Q1 2026 results · BridgeBio commercial update, January 2026 · acoramidis real-world evidence, 2026 · BridgeBio FY2025 10-K and 2026 updates · Pfizer tafamidis sales, 2024 · vutrisiran market projections, 2026 · company financial data · BridgeBio 2026 updates · ATTR-CM competitive landscape, 2026

View the full interactive BBIO report on boothcheck